Login to Your Account



Not So 'Fost'? Rigel RA Drug Could Survive AstraZeneca Hit

By Randy Osborne
Staff Writer

Tuesday, June 4, 2013
Although efficacy below AstraZeneca plc's standard caused the pharma firm to give up rights to fostamatinib, the spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis (RA) met important endpoints, and Rigel Pharmaceuticals Inc. could find another partner and explore new diseases with it.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription